Addiction & Dependence
Cannabis use disorder: prevalence, mechanisms, and treatment
Cannabis use disorder (CUD) is a clinically recognized condition affecting approximately 9% of people who ever use cannabis and 17% of those who begin in adolescence. As potency has increased and use has become more normalized, understanding the neurobiology of cannabis dependence, its risk factors, and evidence-based treatment options has become increasingly important for clinicians and public health.
What the Research Shows
Cannabis use disorder is defined in DSM-5 as a problematic pattern of cannabis use leading to clinically significant impairment or distress, with at least 2 of 11 criteria met within a 12-month period. The neurobiological basis involves CB1 receptor downregulation and desensitization with chronic heavy use, disrupting endogenous endocannabinoid signaling and producing a hypodopaminergic state that drives compulsive use. Withdrawal syndrome — characterized by irritability, insomnia, anxiety, decreased appetite, and physical discomfort — occurs in approximately 50% of daily users upon cessation and is a primary driver of relapse. Risk factors for CUD include early age of initiation, daily use, high-potency products (high THC:CBD ratio), genetic vulnerability (particularly FAAH and CNR1 polymorphisms), and co-occurring psychiatric disorders. Paradoxically, CBD may have therapeutic potential in CUD treatment — its ability to modulate CB1 signaling without direct agonism, combined with anxiolytic and sleep-promoting properties, positions it as a candidate for withdrawal management. Behavioral therapies (CBT, motivational enhancement) remain the most evidence-based treatments; no pharmacotherapy is currently FDA-approved for CUD.
Key Findings
9% of cannabis users develop cannabis use disorder
Well-StudiedLifetime CUD risk is ~9% for all users, rising to 17% for those who initiate in adolescence and ~50% for daily users. Risk has likely increased with rising THC potency.
Cannabis withdrawal syndrome is clinically significant
Well-StudiedDSM-5 recognized cannabis withdrawal affects ~50% of daily users. Symptoms peak at 2–6 days after cessation and resolve within 2 weeks, but drive high relapse rates.
Adolescent initiation dramatically increases CUD risk
Well-StudiedInitiating cannabis use before age 18 is associated with 4x higher risk of CUD, greater severity of dependence, and worse cognitive outcomes than adult initiation.
CBD may reduce cannabis craving and withdrawal symptoms
Emerging ResearchPreliminary RCT data show CBD (400–800mg/day) reduces cannabis use, craving, and withdrawal severity in CUD patients, with a favorable safety profile.
High-potency cannabis products accelerate CUD development
Emerging ResearchCohort studies find users of high-potency cannabis (>10% THC) develop CUD faster and at higher rates than users of lower-potency products.
Featured Studies
View all in libraryCommon Questions
What We Still Don't Know
These are open research questions — areas where the evidence is insufficient or actively contested.
- 1Will CBD receive FDA approval for cannabis use disorder following Phase 3 trials?
- 2Does rising cannabis potency explain the observed increase in CUD prevalence since legalization?
- 3What is the minimum THC:CBD ratio that meaningfully reduces psychosis and CUD risk?
- 4Are there genetic biomarkers that can identify individuals at high risk for CUD before initiation?
- 5Does cannabis use disorder have distinct neurobiological subtypes that require different treatments?
- 6What is the long-term cognitive trajectory of CUD patients who achieve sustained abstinence?
- 7How does cannabis use disorder interact with opioid use disorder in the context of opioid-sparing strategies?